KCT0005576
Not Yet Recruiting
N/A
A phase II study of neoadjuvant chemoradiotherapy with protons for resectable esophageal cancer
ational Cancer Center0 sites68 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ational Cancer Center
- Enrollment
- 68
- Status
- Not Yet Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Good Organ Function
- •(1\) Absolute neutrophil count \> 1500/mm3, platelets \=100,000/mm3, Hemoglobin \= 9g/dl
- •(2\) CCr \= 20mL/min (Cockroft\-Gautl))
- •(3\) Total billrubin \=1\.5X UNL, AST /ALT \=2\.5X UNL
- •\- FEV1\> 1\.5L
- •\- Singed Informed Consesnt
Exclusion Criteria
- •1\. Have a history of esophageal Cancer who previously received topical therapy such as esophageal submucosal resection, surgery, radiation therapy or chemotherapy.
- •2\. Have a distant metastasis lesion
- •3\. Have a history of severe hypersenstivity to mannitol, paclitacxel, neoplatin or platinum based durg.
- •4\. Have a hearing damage.
- •5\. Have a hemorrhagic tumor
- •6\. Have a additional malignancy is not disease free for more than 3 years. (except cured basal or smuamous skin cancer, cervial carcinoma in situ)
- •7\. pregnant or breastfeeding
- •8\. uncontrolled pychiatric disease, severy head injury, chronic alcoholism or drug addiction. CNS disease.
- •9 Have a weight loss of more than 10% during recent 6 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
A phase I/II study of neoadjuvant chemoradiotherapy for pancreatic cancer.JPRN-UMIN000042932The Jikei University school of medicine58
Completed
N/A
Phase II study of neoadjuvant chemoradiotherapy of s-1 and cisplatin for advanced gastric cancer with lymph node metastases (Neo-KOGC04 study)Advanced Gastric CancerJPRN-UMIN000014331School of Medicine, Keio University30
Active, Not Recruiting
N/A
Phase II Studie: Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom - BevXelOx-RTPatienten mit lokal fortgeschrittenem Rektumkarzinom im Klinischen Stadium II/IIIEUCTR2007-001558-21-DEniversitätsklinikum Schleswig-Holstein
Recruiting
Phase 2
eoadjuvant AI therapy for retroperitoneal de-differentiated liposarcomaJPRN-jRCTs041230007Kurimoto Keisuke23
Recruiting
N/A
A phase II study of Neoadjuvant chemotherapy plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage ovarian cancer (TRU-D)NeoplasmsKCT0003742Yonsei University Health System, Severance Hospital24